Sofie Biosciences Images First Gastrointestinal Cancer Patient in Phase II Radiopharmaceutical Trial
The firm is evaluating its fluorine-18 labeled PET imaging agent as a tool for identifying patients with FAP-expressing gastrointestinal cancers.
CARsgen to Study CLDN18.2 Drug, Roche's Tecentriq for Gastric Cancer Patients in China
China's NMPA cleared the firm's IND to study AB011 plus Tecentriq as first-line treatment for advanced CLDN18.2-positive gastric or gastroesophageal junction cancers.
NMPA Clears CARsgen Therapeutics' IND for CAR T-Cell Therapy in CLDN18.2-Positive Pancreatic Cancer
Following signs of efficacy against pancreatic cancer in preclinical studies, CARsgen plans to evaluate CT041 as an adjuvant therapy in a clinical trial.
Gastric Cancer Risk Variants, Pathogen Interactions Found in Retrospective Study
Sequencing on gastric cancer cases and controls helped flag nine susceptibility genes, including genes that interact with Helicobacter pylori infection to bump up risk.
Astellas Bullish on Zolbetuximab's Prospects in Gastric Cancer After Two Positive Phase III Readouts
The firm will submit data from the GLOW and SPOTLIGHT studies to regulators and seek approval for zolbetuximab plus chemo in CLDN18.2-positive HER2-negative advanced gastric cancer.